|
Arena Pharmaceuticals, Inc.
|
| Link ID |
246353 |
| Title |
Arena Pharmaceuticals, Inc. |
| Url |
http://www.arenapharm.com/ |
| Description |
Receptor-based drug discovery in the fields of diabetes, obesity, cardiovascular, sleep disorders, neurodegeneration, schizophrenia, depression and anxiety. Comprehensive profile of company in San Diego, California. (Nasdaq: ARNA) |
| Category |
Biotechnology and Pharmaceuticals > Pharmaceuticals > Biopharmaceuticals > Research and Development |
| Keywords |
|
| Date |
Jul 19, 2006 |
| Contact Name |
|
| Email |
|
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Biotechnology and Pharmaceuticals > Pharmaceuticals > Biopharmaceuticals > Research and Development |
| 1. |
Imclone Systems Inc.
|
|
|
Researches and develops growth factor blockers and anti-cancer vaccines. Includes clinical programs, investor details and overview of company in New York City. (Nasdaq: IMCL)
|
| 2. |
Optimer Pharmaceuticals
|
|
|
Develops late-stage anti-infective and preclinical antibiotics by carbohydrate technology.
|
| 3. |
Nephros Therapeutics, Inc.
|
|
|
Specialist in the design, development, and marketing of human cell replacement therapy systems, targeting inflammatory disease. Includes directions to research labs at Ann Arbor, Michigan, and corporate offices in Lincoln, Rhode Island.
|
| 4. |
Synaptic Pharmaceutical Corp.
|
|
|
Applies human receptor-targeted drug design technology to discover and clone genes and to design G protein-coupled receptor agonist and antagonists. Based in Paramus, New Jersey. (Nasdaq: SNAP)
|
| 5. |
Hemobiotech Inc.
|
|
|
Developer of blood substitute, aiming to address intrinsic hemoglobin toxicity. Introduction to company and their work, with form to contact Dallas, Texas.
|
|
|
